RLMD
Relmada Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +15.4% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 52 | +17 | 37.42M | $258.91M | +22 | −5 |
| Q1 2026 | 36 | +1 | 37.39M | $260.09M | +3 | −2 |
| Q4 2025 | 35 | +5 | 26.87M | $129.62M | +5 | n/a |
| Q3 2025 | 8 | 0 | 1.94M | $3.90M | n/a | n/a |
| Q2 2025 | 7 | +1 | 1.68M | $1.01M | +1 | n/a |
| Q1 2025 | 4 | 0 | 703.26K | $189,901 | n/a | n/a |
| Q4 2024 | 4 | -3 | 701.66K | $364,906 | n/a | −3 |
| Q3 2024 | 6 | 0 | 1.19M | $3.85M | n/a | n/a |
| Q2 2024 | 6 | n/a | 857.82K | $2.57M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 508.00K | 0.0% | $1.02M | 0.0% | Held | 2 | SEC ↗ |
| 2 | The Vanguard Group ✦ (passive) | 418.58K | +15.0% | $841,346 | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 3 | Geode Capital Management ✦ (passive) | 296.21K | -2.0% | $595,533 | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 4 | Marshall Wace ✦ | 272.05K | +76.0% | $546,827 | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 5 | Two Sigma Investments ✦ | 173.61K | +82.0% | $348,964 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 169.70K | +13.1% | $341,097 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 7 | State Street Global Advisors ✦ (passive) | 101.82K | -4.6% | $204,658 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | Morgan Stanley ✦ | 1.04K | n/a | $2,088 | 0.0% | n/c | 1 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 103 holders, 83.66M shares, $576.39M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer, Director · Chief Executive… · 100.00K sh @ 4.10 · $410,000
Officer · Chief Financial… · 79.80K sh @ 4.25 · $339,150
Officer, Director · Chief Executive… · 100.00K sh @ 4.18 · $418,000
Officer · Chief Financial… · 120.20K sh @ 4.20 · $504,840
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology